Velocity Nova Sp. z o.o.

Velocity Nova Sp. z o.o. is conducting a series of studies aimed at improving outcomes for patients with atherosclerotic cardiovascular disease, atrial fibrillation, coronary artery disease and high‑risk dyslipidaemia. The trials evaluate new lipid‑lowering agents, anticoagulant safety profiles, and innovative therapies to reduce heart attacks, strokes and cardiovascular death.

• Inclisiran’s impact on major adverse cardiovascular events
• Abelacimab versus rivaroxaban for bleeding risk
• CagriSema’s efficacy in preventing MACE
• Obicetrapib compared with bempedoic acid for LDL‑C reduction
• RBD1119 safety assessment in coronary artery disease patients

The site hosts eight active trials led by four investigators, offering patients in Zamość, Poland access to cutting‑edge cardiovascular research.

Research at Velocity Nova focuses on the blood‑coagulation system, exploring how novel agents influence clotting factors and bleeding risk in patients with cardiovascular conditions. These investigations aim to refine therapeutic strategies that balance efficacy with safety for disorders of the haemic system.

• Pharmacodynamic effects of RBD1119 on factor XI activity
• Comparative safety of abelacimab and rivaroxaban regarding major bleeding

By integrating haemostatic endpoints, the centre contributes valuable data to the broader field of haemic and lymphatic disease management.

The clinic is evaluating interventions for obesity and type 2 diabetes with heightened cardiovascular risk. Studies compare novel agents to standard insulin therapy and assess effects on body weight, glycaemic control and heart‑related outcomes.

• Ribupatide’s effect on weight loss and HbA1c
• Zenagamtide versus insulin glargine for glycaemic management
• Combination of metabolic endpoints with cardiovascular event monitoring

These trials provide participants with access to potentially more effective metabolic treatments while monitoring cardiovascular safety.

Velocity Nova conducts vaccine and therapeutic studies targeting respiratory viruses, including COVID‑19 and influenza. The research assesses immune responses to combination vaccines and evaluates safety in older adults, aiming to improve protection against seasonal and emerging viral threats.

• Combination SARS‑CoV‑2 spike and high‑dose influenza vaccine immunogenicity
• Non‑inferiority of influenza‑specific immune responses across vaccine strains
• Evaluation of SARS‑CoV‑2 variant‑specific antibody responses

Through these investigations, the centre supports public health efforts to enhance vaccine efficacy for vulnerable populations.